We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PIRS market cap is 1.15B. The company's latest EPS is USD -0.2483 and P/E is -47.04.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 5.37M | 5.85M | 1.94M | 20.06M | 19.52M |
| Operating Income | -12.17M | -11.52M | -15.51M | 2.06M | 3.09M |
| Net Income | -9.74M | -8.1M | -13.18M | 3.98M | -10.75M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 46.28M | 29.32M | 31.42M | 25.9M | 42.81M |
| Operating Income | -27.16M | -33.92M | -51.83M | -43.47M | -15.84M |
| Net Income | -25.47M | -37.23M | -45.74M | -33.28M | -24.54M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 99.16M | 95.49M | 82.26M | 87.54M | 59.38M |
| Total Liabilities | 63.4M | 67.56M | 66.8M | 47.05M | 28.87M |
| Total Equity | 35.77M | 27.93M | 15.46M | 40.5M | 30.51M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 141.1M | 105.01M | 153.56M | 95.49M | 38.68M |
| Total Liabilities | 89.75M | 73.98M | 102.81M | 67.56M | 11.92M |
| Total Equity | 51.35M | 31.03M | 50.76M | 27.93M | 26.76M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -47M | -59.93M | -11M | -24.43M | -34.15M |
| Investing | -22.34M | -21.24M | 11.9M | 10.54M | 8.55M |
| Financing | 7.12M | 7.21M | N/A | 19.78M | 19.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -52.47M | -45.9M | -7.66M | -59.93M | -53.82M |
| Investing | 9.84M | 39.21M | -949k | -21.24M | 12M |
| Financing | 32.17M | 10.12M | 59.13M | 7.21M | 19.8M |
| Market Cap | 1.15B |
| Price to Earnings Ratio | -47.04 |
| Price to Sales Ratio | 26.97 |
| Price to Cash Ratio | 66.36 |
| Price to Book Ratio | 43.15 |
| Dividend Yield | - |
| Shares Outstanding | 98.85M |
| Average Volume (1 week) | 22.89k |
| Average Volume (1 Month) | 435.11k |
| 52 Week Change | -80.74% |
| 52 Week High | 80.80 |
| 52 Week Low | 10.888 |
| Spread (Intraday) | 0.69 (5.78%) |
| Company Name | Pieris Pharmaceuticals Inc |
| Address |
3773 howard hughes pkwy las vegas, nevada 89169 |
| Website | https://www.pieris.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
